List of Excipients in Branded Drug PANCURONIUM BROMIDE

Generic Drugs Containing PANCURONIUM BROMIDE

Company	Ingredient	NDC	Excipient
Hospira Inc	pancuronium bromide	0409-4646	ACETIC ACID
Hospira Inc	pancuronium bromide	0409-4646	BENZYL ALCOHOL
Hospira Inc	pancuronium bromide	0409-4646	SODIUM ACETATE ANHYDROUS

What are the Most Frequently-Used Excipients in PANCURONIUM BROMIDE?

# Of NDCs	Excipient
1	ACETIC ACID
1	BENZYL ALCOHOL
1	SODIUM ACETATE ANHYDROUS

Pancuronium Bromide Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Pancuronium bromide is an established, injectable neuromuscular-blocking agent with limited patent exposure and a commodity-like market structure. The strongest commercial opportunities are not new-molecule exclusivity plays. They are formulation reliability, preservative-free presentation, ready-to-administer packaging, global supply continuity, and differentiated hospital procurement economics.

The product is a small-molecule prescription injectable, not a biologic. Biosimilar competition is therefore irrelevant. Generic competition, hospital tender pricing, manufacturing capacity, drug-shortage exposure, and regulatory compliance determine commercial performance.

What is the regulatory status of pancuronium bromide?

Pancuronium bromide is an FDA-approved nondepolarizing neuromuscular blocker administered intravenously during anesthesia and controlled ventilation. It is also used as an adjunct in surgical procedures and intensive-care settings when skeletal-muscle relaxation is required.

Attribute	Pancuronium bromide
Active ingredient	Pancuronium bromide
Drug class	Aminosteroid nondepolarizing neuromuscular blocker
Route	Intravenous injection
Typical marketed strengths	1 mg/mL and 2 mg/mL presentations
Dosage form	Sterile injectable solution
Therapeutic setting	Operating room, intensive care, controlled ventilation
FDA pathway	NDA-originator and abbreviated generic pathways
Biosimilar status	Not applicable
Primary competition	Vecuronium, rocuronium, cisatracurium, atracurium, succinylcholine
Main procurement buyers	Hospitals, group purchasing organizations, government accounts, anesthesia providers

FDA labeling identifies pancuronium bromide injection as a sterile parenteral product intended for intravenous administration. The label requires trained administration, airway support, and appropriate reversal and monitoring capabilities because the drug causes respiratory-muscle paralysis (U.S. Food and Drug Administration [FDA], n.d.-a).

Pancuronium has a slower onset and longer duration than several newer neuromuscular blockers. That pharmacologic profile limits its use in some operating-room protocols but can support demand in selected hospital and intensive-care applications.

What excipients are used in pancuronium bromide injection?

Commercial pancuronium bromide injections generally use a simple aqueous formulation. The core excipient strategy is based on isotonicity, pH control, chemical stability, and compatibility with sterile manufacturing.

Public FDA labeling for pancuronium bromide injection identifies sodium chloride as a formulation component and describes pH adjustment with suitable acids or bases. Product-specific inactive-ingredient details must be confirmed against the applicable manufacturer label and FDA listing because excipient quantities and adjustment agents can differ by supplier (FDA, n.d.-a; FDA, n.d.-b).

Formulation function	Likely excipient approach	Commercial objective
Vehicle	Water for Injection	Sterile, low-particulate parenteral base
Tonicity	Sodium chloride	Reduce injection-site and hemolysis risk
pH control	Acetate, hydrochloric acid, sodium hydroxide, or equivalent adjustment system, depending on product	Maintain chemical stability and tolerability
Antimicrobial preservation	Preferably none for single-dose presentation	Support preservative-free hospital use
Chelation	Generally unnecessary unless stability data justify inclusion	Avoid unnecessary formulation complexity
Surfactant	Generally unnecessary for a clear aqueous solution	Reduce extractables and compatibility risk
Container protection	Glass vial, polymer vial, or ampoule selected through stability studies	Control adsorption, leachables, and oxygen exposure

The low excipient burden creates a narrow technical differentiation window. A company should not add excipients merely to create a longer ingredient list. Each additive creates new extractables, leachables, compatibility, toxicology, and regulatory obligations.

What pH and tonicity strategy is appropriate?

The formulation should target a pH range supported by forced-degradation, accelerated-stability, and real-time stability data. The commercial objective is not the highest possible pH stability in isolation. It is a balanced pH that preserves pancuronium potency, limits degradants, maintains clarity, and minimizes injection discomfort.

An isotonic or near-isotonic formulation is preferable for routine hospital administration. Sodium chloride is commercially attractive because it is familiar to regulators, inexpensive, widely available, and compatible with standard parenteral manufacturing.

A buffered formulation may improve pH control during shelf life, but buffer selection should be conservative. Acetate and phosphate systems can affect compatibility with infusion fluids, container materials, and other drugs. The buffer capacity should be sufficient to control drift without making the product difficult to dilute or co-administer.

Which excipient strategy offers the best commercial opportunity?

The highest-value strategy is a preservative-free, ready-to-use or ready-to-dilute injectable with robust stability and low hospital handling burden.

Strategy 1: Preservative-free single-dose vial

A preservative-free single-dose vial is the most defensible baseline product. It aligns with modern hospital preferences for reducing preservative exposure and simplifying medication-use protocols.

Advantages include:

• Lower concern about benzyl alcohol or other preservative-related toxicity.
• Better positioning for neonatal, pediatric, intensive-care, and high-acuity use.
• Simplified compatibility with institutional injectable-drug policies.
• Easier differentiation from older multidose products.
• Reduced need for antimicrobial-preservative justification.

The principal disadvantage is higher packaging and manufacturing cost per administered dose compared with a multidose container. The cost can be offset through larger vial sizes, improved fill-finish efficiency, and hospital contracts.

Strategy 2: Ready-to-administer syringe

A prefilled syringe can reduce dose-preparation steps, labeling errors, and nursing workload. It is most relevant for emergency departments, operating rooms, transport teams, and standardized anesthesia kits.

The commercial barriers are substantial:

• Higher unit cost.
• More complex device qualification.
• Need for accurate dose delivery at low fill volumes.
• Greater extractables and leachables assessment.
• Potential human-factors and container-closure requirements.
• More demanding cold-chain and shipping validation if the device is sensitive.

A prefilled syringe is more likely to command a premium than a reformulated vial, but the addressable market is narrower. The product should target a defined workflow problem, such as rapid access in an anesthesia cart or standardized dosing in critical care.

Strategy 3: Dual-strength presentation

Offering both 1 mg/mL and 2 mg/mL strengths can support hospital formulary standardization. The 2 mg/mL product reduces injection volume, while the 1 mg/mL product may facilitate smaller dose adjustments.

Dual-strength commercialization creates operational costs:

• Separate stability programs.
• Separate packaging and labeling.
• Increased inventory complexity.
• Greater risk of strength-selection errors.
• Separate artwork, serialization, and pharmacovigilance controls.

A company should launch the strength with the clearest procurement demand, then add the second strength only where tender or formulary data support it.

Strategy 4: Extended-temperature stability

A product that tolerates short-term temperature excursions has practical value in hospitals, ambulances, military settings, and international distribution. The claim must be supported by real-time and accelerated stability data in the final container.

Temperature-flexible distribution can reduce:

• Shipment rejection.
• Hospital wastage.
• Emergency replacement orders.
• Reliance on tightly controlled cold-chain logistics.

This is a supply-chain advantage rather than an exclusivity right. The commercial value is greatest in regions with unreliable distribution infrastructure.

What formulation patents protect pancuronium bromide?

Pancuronium bromide itself is an old active ingredient, and the core composition is unlikely to support meaningful new-molecule patent protection. Any remaining patent opportunity would likely involve a specific formulation, device, manufacturing process, container system, or use.

Potentially patentable areas include:

Candidate IP area	Patent potential	Commercial relevance
Stable aqueous formulation at a defined pH	Moderate if unexpected stability is demonstrated	Supports lifecycle differentiation
Low-degradant composition	Moderate	Useful for shelf-life and regulatory filings
Prefilled syringe or autoinjector	Moderate to high for device architecture	Supports premium packaging
Ready-to-use diluted presentation	Moderate	Reduces hospital preparation
Novel container-closure system	Moderate	Controls adsorption, leachables, or oxygen ingress
Manufacturing process with improved impurity control	Moderate	Can create quality and cost advantages
New therapeutic use	Low to moderate	Requires clinically credible differentiation
Pancuronium active ingredient itself	Minimal	Core composition is historically mature

A patent application would need more than routine optimization. A narrow pH range, buffer concentration, or sodium chloride level is vulnerable if it represents predictable formulation work. Stronger protection would require data showing an unexpected result, such as materially improved stability, reduced impurity formation, or compatibility that prior formulations did not achieve.

When does pancuronium bromide lose exclusivity?

Pancuronium bromide has no meaningful remaining new-molecule exclusivity in the United States. The active ingredient has been used clinically for decades, and generic competition is established.

Exclusivity category	Current commercial significance
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current product-level barrier identified
Reference-product exclusivity	Expired or commercially immaterial
Core compound patent	Expired
Formulation patents	Product-specific; no broad active barrier identified
Method-of-use patents	No broad current barrier identified
Biosimilar exclusivity	Not applicable

FDA generic entry is therefore governed primarily by abbreviated application requirements, product quality, manufacturing capacity, and supply economics. A new entrant would typically pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence through the applicable regulatory framework. A 505(b)(2) application could be relevant for a materially different presentation, delivery system, or formulation that cannot rely entirely on an ANDA pathway.

What is the Orange Book status of pancuronium bromide?

The Orange Book is relevant for identifying reference-listed drugs, approved applications, patents, and regulatory exclusivities. For pancuronium bromide, the strategic conclusion is that Orange Book-listed exclusivity is not the principal barrier to entry. The product is a mature generic injectable, and commercial control depends more heavily on manufacturing and supply reliability than on listed patent rights (FDA, n.d.-c).

A prospective applicant should review:

• Current reference-listed-drug status.
• Approved strengths and vial sizes.
• Active patent and exclusivity entries, if any.
• Therapeutic-equivalence codes.
• Approved holders and discontinued-product designations.
• Current drug-shortage status.
• FDA inspection history for proposed manufacturing sites.

The Orange Book does not eliminate risk from non-Orange-Book intellectual property. Device patents, trade secrets, manufacturing know-how, and contractual supply arrangements may remain relevant even when no product patent blocks an ANDA.

Are there Paragraph IV challenges or pancuronium bromide litigation?

No major current Paragraph IV litigation or settlement structure is generally associated with pancuronium bromide’s mature generic market. The absence of high-profile litigation is commercially favorable for entry but also indicates limited opportunity to extract value from patent settlement economics.

A Paragraph IV filing would be most relevant only if an applicant faced a currently listed patent covering a specific formulation, method of use, or device. For a conventional sterile aqueous pancuronium injection, the more probable risks are:

• ANDA deficiency letters.
• Sterility-assurance failures.
• Visible or subvisible particulate findings.
• Extractables and leachables concerns.
• Container-closure integrity failures.
• Out-of-specification potency or impurity results.
• Manufacturing-site inspection deficiencies.
• Supply interruptions after approval.

How strong is the patent estate for pancuronium bromide?

The core patent estate is weak from a blocking perspective and potentially useful only for narrow lifecycle products.

Patent factor	Assessment
Compound protection	Very weak or expired
Broad composition protection	Weak
Conventional aqueous injection	Weak unless supported by unexpected stability data
Device presentation	Potentially stronger
Manufacturing process	Potentially valuable as trade secret or narrow patent
Geographic exclusivity	Limited for the active ingredient; country-specific formulation rights may differ
Litigation leverage	Low for conventional generic injection
Licensing value	Low for the active ingredient; higher for proprietary delivery or manufacturing technology

The strongest defensible IP package would combine a narrow formulation patent with a proprietary container or ready-to-administer device. Even then, the commercial value would depend on hospital adoption and procurement differentiation, not on broad exclusion of all pancuronium products.

What manufacturing barriers affect pancuronium bromide supply?

Manufacturing is the main barrier to reliable commercialization.

Critical controls include:

1. Sterile fill-finish capacity. Small injectable markets can be deprioritized by large contract manufacturers. A company needs reserved capacity or a qualified second source.

2. Impurity control. Pancuronium degradation products must remain within specification throughout shelf life. Process control, raw-material quality, pH, oxygen exposure, and light protection should be assessed together.

3. Container compatibility. The product should be evaluated in the selected vial, stopper, seal, syringe barrel, and plunger system. Adsorption and leachables can affect injectable quality.

4. Particulate control. Hospitals and regulators apply strict expectations to parenteral products. Visual inspection, automated inspection, and container-closure integrity are central quality attributes.

5. Supply continuity. A dual-source active pharmaceutical ingredient strategy can be more valuable than a minor excipient reformulation.

6. Serialization and packaging. Injectable products require robust tamper evidence, lot traceability, and anti-counterfeiting controls in relevant markets.

USP standards for sterile preparations and applicable monographs should guide analytical and release specifications (United States Pharmacopeia, n.d.).

How does pancuronium bromide compare with competing neuromuscular blockers?

Product	Commercial position	Excipient and formulation opportunity
Pancuronium bromide	Mature, lower-cost, longer-acting option	Reliable generic supply, preservative-free vial, ready-to-use format
Rocuronium bromide	Common modern alternative with faster onset	Greater market size but stronger competitive pressure
Vecuronium bromide	Established aminosteroid alternative	Similar sterile-injection manufacturing requirements
Cisatracurium besylate	Used where organ-independent elimination is valued	More differentiated clinical positioning
Atracurium besylate	Established nondepolarizing blocker	Formulation and supply reliability remain relevant
Succinylcholine chloride	Rapid-onset depolarizing blocker	Different clinical role; not a direct formulation substitute

Pancuronium should not be positioned as a broad replacement for rocuronium or succinylcholine. Its most credible commercial position is as a cost-efficient, dependable option for institutions that retain it in anesthesia or intensive-care protocols.

What commercial opportunities exist for pancuronium bromide?

Hospital generic supply

A reliable, competitively priced vial can win share in tenders where product shortages have created dissatisfaction with incumbent suppliers. Supply continuity should be a central value proposition.

Preservative-free positioning

A preservative-free product can target hospitals that have removed multidose injectable preservatives from high-acuity formularies. The benefit is strongest when supported by clear labeling and low-particulate performance.

Ready-to-administer packaging

A prefilled syringe or standardized anesthesia-kit presentation can support premium pricing if it reduces preparation time and medication errors. The product should be evaluated against hospital pharmacy labor savings, not vial price alone.

Emerging-market distribution

Pancuronium’s low active-ingredient cost and simple aqueous formulation support international registration. Opportunities are strongest where operating-room demand exists but supplier reliability is poor. Country-specific requirements for sterile manufacturing, local representation, serialization, and language labeling must be addressed.

Contract manufacturing and private label

A manufacturer with validated sterile capacity can supply hospital systems, distributors, or private-label pharmaceutical companies. The principal advantage is operational rather than patent-based.

What generic launch scenarios exist?

Launch model	Investment	Margin potential	Main risk
Conventional single-dose vial	Low to moderate	Low to moderate	Price competition
Dual-strength vial program	Moderate	Moderate	Inventory and medication-error risk
Prefilled syringe	High	Moderate to high	Device development and adoption
Ready-to-use diluted bag	High	Moderate	Stability, volume, and hospital workflow complexity
International low-cost supply	Moderate	Low to moderate	Tender pricing and registration burden
Premium shortage-resilient supply	Moderate	Moderate	Requires dependable capacity and service levels

The lowest-risk launch is a conventional preservative-free vial with a well-controlled aqueous formulation. The highest-value differentiated launch is a prefilled syringe supported by workflow and medication-safety data.

Key Takeaways

• Pancuronium bromide is a mature generic injectable with no meaningful new-molecule exclusivity.
• Biosimilar risk does not apply because pancuronium bromide is a small molecule.
• The preferred baseline formulation is a simple, preservative-free, isotonic aqueous solution.
• Sodium chloride, water for injection, and controlled pH adjustment provide a commercially practical excipient platform.
• Broad formulation patent protection is unlikely without unexpected stability or compatibility results.
• A prefilled syringe, ready-to-administer presentation, or temperature-flexible product offers greater differentiation than adding conventional excipients.
• Manufacturing reliability, sterile fill-finish capacity, impurity control, and container compatibility are the primary entry barriers.
• Conventional vial competition is likely to be price-driven, while device-enabled products may support premium pricing.
• The strongest commercial opportunity is a reliable hospital product with low preparation burden and dependable supply.

FAQs

Can pancuronium bromide be formulated without preservatives?

Yes. A single-dose sterile vial can be formulated without antimicrobial preservatives. This approach reduces preservative-related concerns and aligns with hospital preferences for high-acuity injectable products.

Is a buffered pancuronium bromide formulation patentable?

It may be patentable if the buffer system produces an unexpected and documented improvement in potency retention, impurity control, shelf life, or container compatibility. Routine pH adjustment alone is unlikely to create strong patent protection.

Is pancuronium bromide suitable for a prefilled syringe?

Yes, but the syringe system requires separate evaluation for dose accuracy, extractables and leachables, container-closure integrity, stability, sterilization compatibility, and human factors.

Does pancuronium bromide require cold-chain distribution?

The applicable product label controls storage conditions. A manufacturer can create commercial differentiation through validated room-temperature or excursion stability, but that claim must be supported by stability data in the final marketed container.

Which excipient creates the greatest formulation risk?

The greatest risk usually comes from unnecessary formulation complexity. Buffers, surfactants, preservatives, and chelators can create compatibility and regulatory burdens without improving the product. A minimal, well-characterized formulation is generally preferable.

References

1. U.S. Food and Drug Administration. (n.d.-a). Pancuronium bromide injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.-b). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. United States Pharmacopeia. (n.d.). General chapter <797>: Pharmaceutical compounding - sterile preparations. USP-NF. https://www.usp.org/compounding/general-chapter-797